We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Mapping of Atherosclerotic Plaque Cells Predicts Future Risk of Stroke or Heart Attack

By LabMedica International staff writers
Posted on 21 Nov 2024

Atherosclerosis is the leading cause of cardiovascular diseases like heart attacks and strokes. More...

Over many years, atherosclerotic plaques develop from the accumulation of blood lipids such as cholesterol in the innermost layer of blood vessels. As these plaques become unstable and rupture, blood clots can form, blocking the vessel or traveling to other organs, like the brain. This blockage prevents oxygen from reaching the tissues, leading to a stroke or heart attack. Mortality rates from cardiovascular disease have decreased over the past 50 years due to advancements in understanding disease mechanisms, improved preventive treatments, better diagnostics, and healthier lifestyle choices. Now, a new study has revealed that genetic traits play a role in determining the cellular makeup of atherosclerotic plaques, which influences the likelihood of these plaques causing strokes or heart attacks over time. This discovery could enhance future risk assessment and treatment strategies for patients with atherosclerosis.

Researchers at Karolinska Institutet (Stockholm, Sweden), along with colleagues, successfully mapped the relationship between genetic factors and the composition of different cell types in atherosclerotic plaques. Their research, published in the European Heart Journal, utilized tissue samples from patients with atherosclerosis, stored in a biobank. The researchers used this genetic data to categorize patients into three distinct groups. The first group, with the most severe profiles, typically includes patients who have already experienced a stroke. The second group consists of patients at lower risk, whose vessels contain plaques but have not resulted in a stroke. The third group falls between the other two and often has kidney disease alongside atherosclerosis.

The team has also found preliminary evidence suggesting that this genetic influence might apply to heart attacks as well. This new understanding of how genetics affect plaque cell composition could be integrated with advanced diagnostic imaging and AI to improve assessments of future stroke or heart attack risks and predict how patients might respond to different treatments. While the researchers have conducted similar studies for smaller cohorts in the past, this concept needs to be validated on a larger scale before it can be used in clinical practice. The team plans to continue working on these multi-modal studies to further develop this approach.

“Previous research has shown that heredity is important for the levels of cholesterol, other lipids and circulating immune cells in the blood, but now we see that heredity also affects the composition of smooth muscle cells in the blood vessels of atherosclerotic patients,” says Ljubica Matic, docent at the Department of Molecular Medicine and Surgery at Karolinska Institutet who led the study. “This can affect the development of atherosclerotic plaques, but also the tendency for the plaques to become unstable and cause a stroke.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
New
Next-Generation Sequencing Platform
AXELIOS 1 Platform
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.